HHS to Fund Regeneron's Efforts for Antibody Against Ebola


The collaboration will make available 3 fully-humanized monoclonal antibodies to fight the devastating virus.

The US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response has entered into an agreement with Tarrytown-based Regeneron Pharmaceuticals, Inc to develop a treatment regimen that includes 3 monoclonal antibodies against the Ebola virus.

The company has developed the 3 fully-humanized monclonal antibodies using their propreitory VelociGene and VelocImmune technologies, and will receive $38 million over a 2-year period for further development and manufacturing of the monoclonal antibodies.

Read the associated press release by HHS here.

Related Videos
Kathryn Lindley, MD, FACC
dr jennifer vidrine
dr ryan jacobs
Video 2 - 3 KOLs are featured in, "Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis"
Video 1 - 3 KOLs are featured in, "Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression"
Jessica K. Paulus, ScD, Ontada
dr brian koffman
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Cente
Related Content
CH LogoCenter for Biosimilars Logo